Optimal Design of Drug–Drug Interaction Studies for the GLP‐1 Receptor Agonist Drug Class for Weight Management: Closing a Potential Data Gap

Ähnliche Einträge

• A Phase 1 Study to Evaluate the Potential Drug–Drug Interaction Between Islatravir and Lenacapavir
  von: Haeyoung Zhang, et al.
  Veröffentlicht: (2026)
• Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants
  von: Hamim Zahir, et al.
  Veröffentlicht: (2025)
• Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies
  von: Samira Merali, et al.
  Veröffentlicht: (2024)
• Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants
  von: Shichang Miao, et al.
  Veröffentlicht: (2024)
• Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023
  von: Sarah Ridge, et al.
  Veröffentlicht: (2024)